Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction

Open access
Pehrson, Alan L., Sanchez, Connie · 2014 · CNS Spectrums

Abstract

Monoamine-based treatments for depression have evolved greatly over the past several years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive dysfunction are still significant. Preclinical and clinical studies using compounds directly targeting glutamatergic neurotransmission present new opportunities for antidepressant treatment, with ketamine having a surprisingly rapid and sustained antidepressant effect that is presumably mediated through glutamate-dependent mechanisms. While direct modulation of glutamate transmission for antidepressant and cognition-enhancing actions may be hampered by nonspecific effects, indirect modulation through the serotonin (5-HT) system may be a viable alternative approach. Based on localization and function, 5-HT can modulate glutamate neurotransmission at least through the 5-HT 1A, 5-HT 1B, 5-HT 3, and 5-HT 7 receptors, which presents a rational pharmacological opportunity for modulating glutamatergic transmission without the direct use of glutamatergic compounds. Combining one or more of these glutamate-modulating 5-HT targets with 5-HT transporter inhibition may offer new therapeutic opportunities. The multimodal compounds vortioxetine and vilazodone are examples of this approach with diverse mechanisms, and their different clinical effects will provide valuable insights into serotonergic modulation of glutamate transmission for the potential treatment of depression and associated cognitive dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1092852913000540

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A schematic diagram of the hypothesized modulatory role of 5-HT receptors on glutamatergic neurotransmission. A glutamatergic pyramidal neuron and several GABA interneurons expressing the 5-HT3, 5-HT1A, 5-HT7, and 5-HT1B receptors on either dendrites or axon terminals are shown. The multimodal compounds vortioxetine and vilazodone and their possible sites of action are also shown. Note that 5-HT1A, 5-HT1B, and 5-HT7 receptors may be localized on different neuronal populations. Symbols used: VLA, vilazodone; VOR, vortioxetine.
Figure 1 A schematic diagram of the hypothesized modulatory role of 5-HT receptors on glutamatergic neurotransmission. A glutamatergic pyramidal neuron and several GABA interneurons expressing the 5-HT3, 5-HT1A, 5-HT7, and 5-HT1B receptors on either dendrites or axon terminals are shown. The multimodal compounds vortioxetine and vilazodone and their possible sites of action are also shown. Note that 5-HT1A, 5-HT1B, and 5-HT7 receptors may be localized on different neuronal populations. Symbols used: VLA, vilazodone; VOR, vortioxetine.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 153 references

Research works printed but not linked: 1

  1. Westrich, 2012, In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets, Int J Psychiatry Clin Pract, 5, 47

Cited by

See all 161

Metadata

Authors
Pehrson, A. L., & Sanchez, C.
Affiliations
Lundbeck (United States) (US)
Venue
CNS Spectrums
Published
2013-08-01
Volume
19
Issue
2
Pages
121-133
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W2109860355
Cited by
161
References
153
Citations by year
2026: 7 · 2025: 6 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 19 · 2018: 9 · 2017: 21 · 2016: 15 · 2015: 25 · 2014: 13 · 2013: 4
FWCI
2.38
Type
journal article
Language
en
Open access
Locations
  • CNS Spectrums (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
serotonergic modulation, glutamatergic neurotransmission, depression, cognitive impairment, 5-HT1A receptor, 5-HT1B receptor, 5-HT3 receptor, 5-HT7 receptor, vortioxetine, vilazodone, ketamine, antidepressant efficacy, multimodal antidepressant
MeSH terms
Animals, Cognition Disorders, Depression, Humans, Synaptic Transmission, Serotonin, Serotonin Agents, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. https://app.cochat.ai/papers/10.1017/s1092852913000540
The paper
Pehrson, A. L., & Sanchez, C. (2014). Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums. https://doi.org/10.1017/s1092852913000540

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.